lucius卢修斯考比替尼 Cobimetinib黑色素瘤

考比替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Cobimetinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

黑色素瘤

Composition:
cach film-coated tablet contains Cobimetinio
umarate 22 mc cgvivalent to Cobimetinib ....... 0mg
ndication:

LUCiUS

For the treatment of adult panents with unresectable

PHARMACEUTICALS

V600K mutstion. in comb
con with vemurafenib.
As a siagle agent for the treatment of adult patients

组织细胞肿瘤

With histiocytic nannleny

LuciCob

Confirm the nracane
or te presence of BRAF V600E or V600
mutation in turor specimens prior to intiifion of
LIcoo with vemurafenib for patients with

melanona

20mg

ended dose is 60 mg orally once daily
for the first 2l days of each 28-day cycle until disease
progression or unacceptable tosicity, Tate

Cobimetinib Tablets

Sterage: in a dry place and store at 20°C to 25°C

FDA批准

Warning
Kero medicine d
dicine out ofreach of Children. Do not
adrainister LuciCob during Pregnancy and Lactation.
PLEASESEEPACKAGEINSERT

Rx Only

Manufactured and Marketed by:
Thongmang village. Xaythany district, Vientiane

权威认证

www.lucus.a

Warning :To be sold by retail on prescriotion
of regustered pby

63 Tablets

口碑质量

适应症:

考比替尼是一种激酶抑制剂,其适应症为:
· 与维莫非尼联合用于治疗携带BRAF V600E或V600K突变的不可切除或
转移性黑色素瘤成年患者。
作为单药用于治疗组织细胞肿瘤成年患者。
推荐剂量:
·黑色素瘤患者开始使用考比替尼联合维莫非尼治疗前,应确认肿瘤样本中
是否存在BRAF V600E或V600K突变。
·推荐剂量为每日一次,每次60mg,连续服用21天,每28天为一个疗程,直
至病情进展或出现不可接受的毒性。
可与食物同服或单独服用。